Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

How else can we approach prostate cancer biomarker discovery?

Drake RR, Angel PM, Wu J, Pachynski RK, Ippolito JE.

Expert Rev Mol Diagn. 2019 Sep 10:1-3. doi: 10.1080/14737159.2019.1665507. [Epub ahead of print] No abstract available.

PMID:
31498690
2.

Diagnostic performance of prostate multiparametric magnetic resonance imaging in African-American men.

Henning GM, Vetter JM, Drake BF, Ippolito JE, Shetty AS, Andriole GL, Kim EH.

Urology. 2019 Aug 13. pii: S0090-4295(19)30715-0. doi: 10.1016/j.urology.2019.08.007. [Epub ahead of print]

PMID:
31419432
3.

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.

Mason BR, Eastham JA, Davis BJ, Mynderse LA, Pugh TJ, Lee RJ, Ippolito JE.

J Natl Compr Canc Netw. 2019 May 1;17(5):506-513. doi: 10.6004/jnccn.2019.7306.

PMID:
31085758
4.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
5.

The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors.

Pickersgill NA, Vetter JM, Raval NS, Andriole GL, Shetty AS, Ippolito JE, Kim EH.

Urology. 2019 May;127:68-73. doi: 10.1016/j.urology.2019.01.035. Epub 2019 Feb 23.

PMID:
30807773
6.

Calcium carbonate nanoparticles stimulate tumor metabolic reprogramming and modulate tumor metastasis.

Som A, Raliya R, Paranandi K, High RA, Reed N, Beeman SC, Brandenburg M, Sudlow G, Prior JL, Akers W, Mah-Som AY, Habimana-Griffin L, Garbow J, Ippolito JE, Pagel MD, Biswas P, Achilefu S.

Nanomedicine (Lond). 2019 Jan;14(2):169-182. doi: 10.2217/nnm-2018-0302. Epub 2018 Dec 6.

PMID:
30730790
7.

Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.

Bhat NR, Vetter JM, Andriole GL, Shetty AS, Ippolito JE, Kim EH.

Urology. 2019 Apr;126:152-157. doi: 10.1016/j.urology.2018.12.010. Epub 2018 Dec 20.

PMID:
30580005
8.

Imaging in Prostate Cancer: Magnetic Resonance Imaging and Beyond.

Ludwig DR, Fraum TJ, Fowler KJ, Ippolito JE.

Mo Med. 2018 Mar-Apr;115(2):135-141.

9.

Prostate cancer PET tracers: essentials for the urologist.

Fraum TJ, Ludwig DR, Kim EH, Schroeder P, Hope TA, Ippolito JE.

Can J Urol. 2018 Aug;25(4):9371-9383. Review.

10.

Synergy of Sex Differences in Visceral Fat Measured with CT and Tumor Metabolism Helps Predict Overall Survival in Patients with Renal Cell Carcinoma.

Nguyen GK, Mellnick VM, Yim AK, Salter A, Ippolito JE.

Radiology. 2018 Jun;287(3):884-892. doi: 10.1148/radiol.2018171504. Epub 2018 Mar 20.

PMID:
29558292
11.

Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.

Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE.

Front Oncol. 2017 Aug 18;7:178. doi: 10.3389/fonc.2017.00178. eCollection 2017.

12.

Sexual dimorphism in glioma glycolysis underlies sex differences in survival.

Ippolito JE, Yim AK, Luo J, Chinnaiyan P, Rubin JB.

JCI Insight. 2017 Aug 3;2(15). pii: 92142. doi: 10.1172/jci.insight.92142. eCollection 2017 Aug 3.

13.

Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group.

Vargas HA, Huang EP, Lakhman Y, Ippolito JE, Bhosale P, Mellnick V, Shinagare AB, Anello M, Kirby J, Fevrier-Sullivan B, Freymann J, Jaffe CC, Sala E.

Radiology. 2017 Nov;285(2):482-492. doi: 10.1148/radiol.2017161870. Epub 2017 Jun 22.

14.

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Feb;77(2):123-144. doi: 10.1002/pros.23260. Epub 2016 Sep 28. Review.

PMID:
27679977
15.

Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.

Ippolito JE, Brandenburg MW, Ge X, Crowley JR, Kirmess KM, Som A, D'Avignon DA, Arbeit JM, Achilefu S, Yarasheski KE, Milbrandt J.

PLoS One. 2016 Jul 20;11(7):e0159675. doi: 10.1371/journal.pone.0159675. eCollection 2016.

16.
17.

Monodispersed calcium carbonate nanoparticles modulate local pH and inhibit tumor growth in vivo.

Som A, Raliya R, Tian L, Akers W, Ippolito JE, Singamaneni S, Biswas P, Achilefu S.

Nanoscale. 2016 Jul 7;8(25):12639-47. doi: 10.1039/c5nr06162h. Epub 2016 Jan 8.

18.

A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.

Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Piwnica-Worms D.

Cancer Discov. 2014 Jul;4(7):828-39. doi: 10.1158/2159-8290.CD-13-0572. Epub 2014 Apr 16.

19.

A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer.

Ippolito JE, Piwnica-Worms D.

PLoS One. 2014 Feb 13;9(2):e88667. doi: 10.1371/journal.pone.0088667. eCollection 2014.

20.

Current concepts in neuroendocrine cancer metabolism.

Ippolito JE.

Pituitary. 2006;9(3):193-202. Review.

PMID:
17001465
21.

Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers.

Ippolito JE, Merritt ME, Bäckhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI.

Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12505-10. Epub 2006 Aug 8.

22.

Molecular properties of adult mouse gastric and intestinal epithelial progenitors in their niches.

Giannakis M, Stappenbeck TS, Mills JC, Leip DG, Lovett M, Clifton SW, Ippolito JE, Glasscock JI, Arumugam M, Brent MR, Gordon JI.

J Biol Chem. 2006 Apr 21;281(16):11292-300. Epub 2006 Feb 7.

23.

An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, Townsend RR, Gordon JI.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9901-6. Epub 2005 Jul 5.

24.

A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype.

Syder AJ, Karam SM, Mills JC, Ippolito JE, Ansari HR, Farook V, Gordon JI.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4471-6.

25.

Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice.

Hu Y, Ippolito JE, Garabedian EM, Humphrey PA, Gordon JI.

J Biol Chem. 2002 Nov 15;277(46):44462-74. Epub 2002 Sep 11.

26.

Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801.

Hess GP, Ulrich H, Breitinger HG, Niu L, Gameiro AM, Grewer C, Srivastava S, Ippolito JE, Lee SM, Jayaraman V, Coombs SE.

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13895-900.

27.

In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor.

Ulrich H, Ippolito JE, Pagán OR, Eterović VA, Hann RM, Shi H, Lis JT, Eldefrawi ME, Hess GP.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14051-6.

Supplemental Content

Loading ...
Support Center